http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103965180-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 |
| filingDate | 2013-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103965180-B |
| titleOfInvention | Benzsulfamide azoles and thiazole inhibitors of kinases |
| abstract | The invention belongs to pharmaceutical technology field, be specifically related to the benzsulfamide azoles shown in formula (I) and thiazole inhibitors of kinases, its pharmaceutically acceptable salt or its stereoisomer, wherein ring A, R 1 、R 2 、R 3 , X, m, n and p be defined as in the description.The invention still further relates to the preparation method of these compounds, pharmaceutical preparation containing these compounds and pharmaceutical composition, and this compound, its pharmaceutically acceptable salt or its stereoisomer are relevant by the b RAF cancer that causes of sudden change in preparation treatment and/or prevention or application in the medicine of non-cancer-related diseases. |
| priorityDate | 2013-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 356.